Keros Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$244M
R&D
$130M
D&A
$2M
Operating Income
$68M
EBITDA
$69M
Interest Expense
$0
Other Income/Expense
$24M
Pretax Income
$92M
Tax Provision
$5M
Net Income
$87M
Operating Margin
27.7%
Net Margin
35.7%
Effective Tax Rate
5.3%
Deferred Tax Assets
$5M
Deferred Tax Liabilities
—
DTA Valuation Allowance
$98M
Tax Credit Carryforwards
$409K
NOL Carryforwards
$35M
ETR (Continuing Operations)
5.3%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.8%
Operating Lease Cost
$4M
Revenue YoY Variation
-100.0%
Income YoY Variation
132.0%